Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Expression analysis of human B7-H3 (4Ig) on CHO/Human B7-H3 (4Ig) Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human B7-H3 (4Ig) Stable Cell Line or negative control cell using PE-labeled anti-human B7-H3 (4Ig) antibody.
5e5 of anti-B7-H3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human B7-H3 (4Ig), His Tag (Cat. No. B7B-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 (4Ig), His Tag (Cat. No. B7B-H52E7) with an affinity constant of 1.74 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
IBI-3001 | IBI-3001; IBI3001 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
Allogenic B7H3-targeting CAR-γδT Cell Therapy | QH104 Cell; QH-104 Cell | Phase 2 Clinical | Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) | Glioblastoma | Details |
IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
7MW3711 | 7-MW-3711; 7MW3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DB-1311 | DB-1311 | Phase 2 Clinical | Solid tumours; Neoplasm Metastasis | Details | |
IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
YL-201 | YL-201; YL201 | Phase 2 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Prostatic Neoplasms, Castration-Resistant | Details |
Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma, Ewing; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Rhabdomyosarcoma; Head and Neck Neoplasms | Details |
HS-20093 | HS20093; HS-20093 | Phase 2 Clinical | Shanghai Hansoh Biomedical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Osteosarcoma | Details |
124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Choroid Plexus Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Diffuse midline glioma; Hepatoblastoma; Rhabdoid Tumor; Desmoplastic Small Round Cell Tumor; Carcinoma; Rhabdomyosarcoma; Medulloblastoma; Solid tumours; Ependymoma | Details |
CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
UTAA06 | UTAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
TX103 CAR-T cell therapy(Fuzhou Tuoxin Tiancheng Biotechnology) | Phase 1 Clinical | Fuzhou Tuoxin Tiancheng Biotechnology Co Ltd | Solid tumours; Glioma | Details | |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Small Cell Lung Carcinoma; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details | |||
Ifinatamab deruxtecan | DS-7300; DS-7300a; MABX-9001a | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Small Cell Lung Carcinoma | Details |
B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma) | Phase 2 Clinical | Boyuan Runsheng Pharma (Hangzhou) Co Ltd | Solid tumours; Glioblastoma | Details | |
Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Mesothelioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Sarcoma; Neuroblastoma; Neurofibrosarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma | Details |
Vobramitamab duocarmazine | MGC-018 | Phase 2 Clinical | Macrogenics Inc | Liver Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
4SCAR-276 | 4SCAR-276 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
IBI-3001 | IBI-3001; IBI3001 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
Allogenic B7H3-targeting CAR-γδT Cell Therapy | QH104 Cell; QH-104 Cell | Phase 2 Clinical | Suzhou Dushu Lake Hospital (Dushu Lake Hospital Affiliated To Soochow University) | Glioblastoma | Details |
IBI129 | IBI-129; IBI129 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
7MW3711 | 7-MW-3711; 7MW3711 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
MHB088C | MHB-088C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
DB-1311 | DB-1311 | Phase 2 Clinical | Solid tumours; Neoplasm Metastasis | Details | |
IBB-0979 | IBB0979; IBB-0979 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
YL-201 | YL-201; YL201 | Phase 2 Clinical | MediLink Therapeutics Co Ltd | Solid tumours; Prostatic Neoplasms, Castration-Resistant | Details |
Fully Human B7H3 CAR-T Cells Therapy | fhB7H3.CAR-Ts | Phase 2 Clinical | The Affiliated Hospital Of Xuzhou Medical University | Ovarian Neoplasms; Carcinoma, Hepatocellular | Details |
CD-276-targeted Chimeric Antigen Receptor T Cell Therapy | CD276 CAR-T | Phase 2 Clinical | Shenzhen University General Hospital | Pancreatic Neoplasms | Details |
Enoblituzumab | MGA-271; TJ271 | Phase 2 Clinical | Macrogenics Inc | Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma, Ewing; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Wilms Tumor; Carcinoma, Renal Cell; Desmoplastic Small Round Cell Tumor; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Rhabdomyosarcoma; Head and Neck Neoplasms | Details |
HS-20093 | HS20093; HS-20093 | Phase 2 Clinical | Shanghai Hansoh Biomedical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Osteosarcoma | Details |
124I-omburtamab | 124I-8H9; 124I-8H9-(B7-H3) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Y-Mabs Therapeutics Inc | Brain Neoplasms; Glioma | Details |
Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
SCRI-CARB7H3 | SCRI-CARB7H3 | Phase 1 Clinical | Seattle Children'S Hospital | Neuroblastoma; Choroid Plexus Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Glioma; Diffuse Intrinsic Pontine Glioma; Neuroectodermal Tumors, Primitive; Sarcoma; Sarcoma, Clear Cell; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Retinoblastoma; Teratoma; Sarcoma, Synovial; Central Nervous System Neoplasms; Wilms Tumor; Diffuse midline glioma; Hepatoblastoma; Rhabdoid Tumor; Desmoplastic Small Round Cell Tumor; Carcinoma; Rhabdomyosarcoma; Medulloblastoma; Solid tumours; Ependymoma | Details |
CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
KT-095 | KT-095 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Solid tumours | Details |
EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
MGC-026 | MGC026; MGC-026 | Phase 1 Clinical | Macrogenics Inc | Prostatic Neoplasms, Castration-Resistant; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Ovarian Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Solid tumours | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
Autologous CAR-T Cells Targeting B7-H3(Unc Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Ovarian Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms | Details | |
MT-027 | MT-027 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
UTAA06 | UTAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
B7-H3 CAR T-cell therapy(Stanford University) | B7-H3CART | Phase 1 Clinical | Stanford University | Nervous System Diseases | Details |
TX103 CAR-T cell therapy(Fuzhou Tuoxin Tiancheng Biotechnology) | Phase 1 Clinical | Fuzhou Tuoxin Tiancheng Biotechnology Co Ltd | Solid tumours; Glioma | Details | |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
BAT-8009 | BAT8009; BAT-8009 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
TAA-06 | TAA06-UCAR-γδT; TAA-06 | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Solid tumours; Neuroblastoma; Colorectal Neoplasms; Lung Neoplasms; Melanoma | Details |
XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-CD276 CAR T-cell therapy (Persongen ) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Stomach Neoplasms; Small Cell Lung Carcinoma; Osteosarcoma; Neuroblastoma; Lung Neoplasms | Details | |
B7-H3-targeting CAR-T cell therapy | Beijing Tiantan Hospital, Capital Medical University | Details |
This web search service is supported by Google Inc.